C4 Therapeutics (CCCC) KOL event summary

Introduction and agenda

• The session/webinar focused on the evolving multiple myeloma landscape, the role of IKZF1/3 degraders, and cemsidomide's emerging clinical profile, with forward-looking statements included.

• Presenters included the CEO, Chief Medical Officer, and a leading academic clinician/hematologist, covering disease background, therapeutic advances, and cemsidomide's clinical data.

• The agenda included an overview of multiple myeloma, foundational biology of IKZF1/3 degraders, cemsidomide's clinical data, and a Q&A session.

KOL background and credentials

• Dr. Nisha Joseph is an Associate Professor at Emory University and an investigator on the cemsidomide program, recognized for expertise in relapsed refractory multiple myeloma.

• Len Reyno, M.D., serves as Chief Medical Officer.

Market insights and analysis

• Multiple myeloma is the second most common hematologic malignancy in the U.S., with over 35,000 new cases annually and significant unmet need, as 40% of patients do not survive beyond five years.

• The treatment landscape has rapidly evolved, with new classes such as proteasome inhibitors, monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies, and a surge in clinical trials and approvals.

• IKZF1/3 degraders are foundational across all stages of therapy, with next-generation agents like cemsidomide emerging.

• There is a growing post-BCMA and post-GPRC5D patient population, highlighting the need for effective therapies after T-cell redirecting treatments.

• Community oncologists are increasingly adopting bispecific antibodies, with ongoing efforts to make administration feasible outside academic centers.